Stakeholder Engagement in Developing an Electronic Clinical Support Tool for Tobacco Prevention in Adolescent Primary Care.

Children (Basel)

Department of Health Outcomes and Biomedical Informatics, and Institute for Child Health Policy, College of Medicine, University of Florida, 2004 Mowry Road, Gainesville, FL 32610, USA.

Published: December 2018

Following guideline recommendations to promote tobacco prevention in adolescent primary care, we developed a patient-facing clinical support tool. The electronic tool screens patients for use and susceptibility to conventional and alternative tobacco products, and promotes patientā»provider communication. The purpose of this paper is to describe the iterative stakeholder engagement process used in the development of the tool. During the pre-testing phase, we consulted with scientists, methodologists, clinicians, and Citizen Scientists. Throughout the development phase, we engaged providers from three clinics in focus groups. Usability testing was conducted via in-depth, cognitive interviewing of adolescent patients. Citizen Scientists ( = 7) played a critical role in the final selection of educational content and interviewer training by participating in mock-up patient interviews. Cognitive interviews with patients ( = 16) ensured that systems were in place for the feasibility trial and assessed ease of navigation. Focus group participants ( = 24) offered recommendations for integrating the tool into clinical workflow and input on acceptability and appropriateness, and anticipated barriers and facilitators for adoption and feasibility. Engaging key stakeholders to discuss implementation outcomes throughout the implementation process can improve the quality, applicability, and relevance of the research, and enhance implementation success.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306818PMC
http://dx.doi.org/10.3390/children5120170DOI Listing

Publication Analysis

Top Keywords

stakeholder engagement
8
clinical support
8
support tool
8
tobacco prevention
8
prevention adolescent
8
adolescent primary
8
primary care
8
citizen scientists
8
tool
5
engagement developing
4

Similar Publications

Methodological description of knowledge translation: Implementation of clinical practice guidelines into clinical practice.

PM R

January 2025

Board Certified Clinical Specialist in Oncological Physical Therapy, Board Certified Clinical Specialist in Women's Health Physical Therapy, LANA Certified Lymphedema Therapist, Select Medical, ReVital Cancer Rehabilitation, Mechanicsburg, Pennsylvania, USA.

This methodological paper explores the intricacies of implementing evidence-based medicine in the health care sector specifically focusing on the clinical practice guideline (CPG) published by the American Physical Therapy Association's Academy of Oncologic Physical Therapy for diagnosing upper quadrant lymphedema secondary to cancer (diagnosis CPG). Although CPGs are widely available, their implementation into clinical practice remains inconsistent, slow, and complex. To address this challenge, this paper employs the Knowledge-to-Action framework, offering a detailed description of the seven stages through the lens of an in-progress case study on the implementation of the diagnosis CPG.

View Article and Find Full Text PDF

Background: The use of eHealth innovations is becoming increasingly important in improving health outcomes, especially for maternal and newborn health. However, planning and executing these innovations can be challenging due to their complex nature. To provide guidance and clarity on implementation approaches, researchers need to use implementation research (IR) tools.

View Article and Find Full Text PDF

Background: Type 2 diabetes mellitus (T2D) remains a pressing public health concern. Despite advancements in antidiabetic medications, suboptimal medication adherence persists among many individuals with T2D, often due to the high cost of medications. To combat this issue, Blue Cross and Blue Shield of Louisiana (Blue Cross) introduced the $0 Drug Copay (ZDC) program, providing $0 copays for select drugs.

View Article and Find Full Text PDF

Target product profile for cell-based and gene-based therapies to achieve a cure for HIV.

Lancet HIV

January 2025

Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; University College London, London, UK.

This target product profile (TPP) highlights the minimal and optimal characteristics for ex-vivo and in-vivo cell and gene therapy-based products aimed at achieving an HIV cure (ie, durable antiretroviral-free viral control). The need for an effective, safe, scalable, affordable, accessible, and acceptable cure for HIV infection remains a major global priority. The possibilities for cell and gene therapy-based products for an HIV cure are rapidly expanding.

View Article and Find Full Text PDF

Background: Health care innovation faces significant challenges, including system inertia and diverse stakeholders, making regulated market access pathways essential for facilitating the adoption of new technologies. The German Digital Healthcare Act, introduced in 2019, offers a model by enabling digital health applications (DiGAs) to be reimbursed by statutory health insurance, improving market access and patient empowerment. However, the factors influencing the success of these pathways in driving innovation remain unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!